Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Accenture
US Army
Cerilliant
AstraZeneca
McKesson
US Department of Justice
Daiichi Sankyo
Boehringer Ingelheim
Dow

Generated: October 21, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,945,621

« Back to Dashboard

Which drugs does patent 8,945,621 protect, and when does it expire?


Patent 8,945,621 protects VIMOVO and is included in one NDA. There has been one Paragraph IV challenge on Vimovo.

This patent has twelve patent family members in twelve countries.

Summary for Patent: 8,945,621

Title:Method for treating a patient at risk for developing an NSAID-associated ulcer
Abstract: The present disclosure is directed to a method for treating a disease or disorder in a patient at risk of developing an NSAID-associated ulcer by administering to said patient in need thereof a pharmaceutical composition in unit dose form comprising naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof to said at risk patient and thereby decreasing the patient's risk of developing an ulcer.
Inventor(s): Ault; Brian (Wilmington, DE), Hwang; Clara (Wilmington, DE), Orlemans; Everardus (Chapel Hill, NC), Plachetka; John R (Chapel Hill, NC), Sostek; Mark (Wilmington, DE)
Assignee: Pozen Inc. (Chapel Hill, NC) Horizon Pharma USA, Inc. (Deerfield, IL)
Application Number:12/822,612
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Horizon Pharma Usa
VIMOVO
esomeprazole magnesium; naproxen
TABLET, DELAYED RELEASE;ORAL022511-002Apr 30, 2010ABRXYesNo► Subscribe► Subscribe RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS ALSO TAKING LOW DOSE ASPIRIN
Horizon Pharma Usa
VIMOVO
esomeprazole magnesium; naproxen
TABLET, DELAYED RELEASE;ORAL022511-001Apr 30, 2010ABRXYesYes► Subscribe► Subscribe RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS ALSO TAKING LOW DOSE ASPIRIN
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,945,621

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2010263304► Subscribe
Canada2764963► Subscribe
China102481293► Subscribe
Eurasian Patent Organization201290026► Subscribe
European Patent Office2445499► Subscribe
Israel216877► Subscribe
Japan2012531409► Subscribe
South Korea20120030106► Subscribe
Morocco33553► Subscribe
Mexico2011013467► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Baxter
Cipla
Mallinckrodt
Fuji
Chinese Patent Office
Harvard Business School
Johnson and Johnson
Deloitte
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot